Aurora Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Make Smarter Expansion Decisions with the Full Report
This Aurora Balanced Scorecard Analysis gives you a clear, company-specific view of Aurora's financial, customer, internal process, and learning and growth priorities. The page already shows a real preview of the actual analysis, so you can review the content and format before buying. Purchase the full version to get the complete ready-to-use report.
Benefits
Global Medical Leadership
In fiscal 2025, Aurora Cannabis kept medical cannabis at the center of its mix, with the segment driving a large share of revenue and supporting gross margin goals near 50%. The Balanced Scorecard helps track patient retention and specialist physician ties, so Aurora can shift away from lower-margin retail. That focus matters because the medical channel is where Aurora has the clearest edge and the best chance to protect profit.
Operational Lean Excellence
Aurora's operational lean focus is clear in its internal process scorecard: keep production costs below C$0.70 per gram in optimized facilities. With about 2 million square feet of greenhouse space across North America and Europe, the scorecard flags waste fast and keeps managers on weekly checks of yield, labor, and facility spend. That turns cost control from a vague goal into a measurable operating routine.
Integration of Non-Cannabis Revenue
Aurora Cannabis Inc.'s acquisition of Bevo Farms broadens the scorecard to include vegetable propagation, so managers can track a more complex, mixed business in one view. That matters because FY2025 non-cannabis lines can steady cash flow when marijuana sales swing about 5% seasonally. A balanced scorecard also ties traditional agriculture and controlled-environment cultivation to the same targets, making capital, yield, and margin decisions easier to compare.
Strategic International Scaling
Aurora's learning and growth scorecard makes international scaling measurable: teams track 100 percent compliance with local pharma rules in Germany and Australia before launch. In 2025, that replaces guesswork with clear milestones, cuts recall risk across 3 continents, and gives management a faster path to pharmaceutical-grade production.
Innovation and Product Mix
Aurora's scorecard ties R&D to revenue by tracking new launches like high-potency cultivars and oils against total sales targets. It also shows how its 15 proprietary cultivars compare with legacy products on customer satisfaction and price premium, so the team can shift spend to the strongest lines. That keeps the R&D budget focused on terpene-heavy profiles that fit 2026 demand.
Aurora's FY2025 Edge: Medical Margins, Lean Costs, Export Readiness
FY2025, Aurora Cannabis' scorecard benefits show up in higher-margin medical sales, tighter cost control, and clearer export readiness. Its medical focus supports margin discipline near 50%, while production targets below C$0.70 per gram keep waste visible. The mix also helps cash flow with Bevo Farms and 2 million sq. ft. of growing space.
| Benefit | FY2025 signal |
|---|---|
| Margin focus | ~50% |
| Cost control | <C$0.70/g |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Significant Administrative Resource Burden
Tracking complex KPIs across 4 international regions means 12 monthly reporting cycles a year, which usually needs a dedicated analyst team. For Aurora, that adds real overhead to a lean corporate setup.
Those hours and reporting costs could instead support product development or debt reduction, where every dollar has a clearer return.
Reporting Lags in Volatile Markets
Balanced Scorecard reviews every 90 days can lag badly when Canadian wholesale prices or policy rates shift within weeks. Aurora can end up acting on last quarter's data while rivals respond faster to tax changes, supply gluts, or sudden margin swings. In volatile retail, that delay can turn a small pricing miss into a real profit hit.
Internal Focus at the Cost of Market Shifts
By pushing hard to cut SG&A by 15% in 2025, Aurora can over-focus on internal cost goals and miss faster shifts in edibles and vape demand. That blind spot matters because lower-cost legacy rivals can use price cuts to win share while a scorecard centered on expense control looks green. In a market where small taste and pricing changes move volume fast, internal targets alone can hide external risk.
Conflict Between Cash Preservation and Growth
Strict financial KPIs can pit Aurora's $150 million cash pile against R&D spend. If management focuses on quarterly liquidity targets, it may delay learning investments that protect the 2025 pipeline. That can lift near-term cash cover, but it also raises the risk of slower product renewal and weaker growth.
Complexity of International Regulatory Standards
Aurora's scorecard gets noisy when one KPI set must cover Canada, the EU, and Australia. A metric tied to Canada's 10-mg edible cap can look strong at home but fail in two European growth markets where medical-only pharmaceutical rules change product mix, compliance costs, and launch timing. That mismatch can distort margin and growth targets, so management may compare unlike units and miss real regulatory risk.
Balanced Scorecard Risks: Slow, Costly, and Too Blunt for Aurora's Markets
Aurora's Balanced Scorecard can be costly and slow: 4 regions mean 12 monthly reporting cycles, while 90-day reviews can miss fast Canadian pricing and policy shifts. A 15% SG&A-cut target may also crowd out R&D, and one KPI set can blur Canada, EU, and Australia regulatory gaps.
| Drawback | Data |
|---|---|
| Reporting load | 12 monthly cycles |
| Review lag | 90 days |
| SG&A focus | 15% cut target |
| Cash vs R&D | $150 million cash |
Full Version Awaits
Aurora Reference Sources
This is the actual Aurora Balanced Scorecard Analysis document you'll receive after purchase – no sample, no placeholders. The preview shown here is taken directly from the full report, so what you see is exactly what you get. Once purchased, you'll unlock the complete, detailed version in full.
Frequently Asked Questions
Aurora uses the framework to prioritize its 7,000 active medical physician relationships and 3 main international trade hubs. By focusing on the customer perspective, the company can track its goal of a 50 percent gross margin specifically for medical sales. This ensures resources are spent on high-margin segments rather than chasing lower-tier volume in 2 or 3 saturated retail markets.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.